Tier 2 — strong

Efficacy and safety of oral betaine glucuronate in non-alcoholic steatohepatitis. A double-blind, randomized, parallel-group, placebo-controlled prospective clinical study

F Miglio, L C Rovati, A Santoro, I Setnikar
Arzneimittel-Forschung 2000 50(8):722-727

Bibliography

PubMed
PMID 10994156
DOI
10.1055/s-0031-1300279
Funding
Funding was not specified in the indexed record or accessible funding metadata.
Competing interests
A competing-interest declaration was not available in the indexed record or accessible disclosure metadata.

Study snapshot

DesignRandomized controlled trial
ModelHuman participants
Sample191 patients with nonalcoholic steatohepatitis
InterventionBetaine glucuronate plus diethanolamine glucuronate and nicotinamide ascorbate versus placebo
Duration8 weeks
EndpointsLiver measures; Symptoms; Adverse events

What the study showed, in plain terms

Published in 2000, this source examined metabolic health and liver trials. Design: Randomized controlled trial. Sample/model: 191 patients with nonalcoholic steatohepatitis. The exposure or intervention was Betaine glucuronate plus diethanolamine glucuronate and nicotinamide ascorbate versus placebo. Follow-up or treatment period: 8 weeks.

The combination improved reported steatosis, liver-enzyme and symptom measures more than placebo, with similar mild adverse-event rates.

A different betaine formulation with multiple active components. The result cannot be attributed to ordinary anhydrous TMG alone.

Continue with TMG Data Center

Continue with TMG and Liver Health: Human Trials Behind the Claims

Key findings

  • The combination improved reported steatosis, liver-enzyme and symptom measures more than placebo, with similar mild adverse-event rates.
  • The recorded outcome domains were Liver measures; Symptoms; Adverse events.
  • The result applies to the tested exposure: Betaine glucuronate plus diethanolamine glucuronate and nicotinamide ascorbate versus placebo; 8 weeks.

What this study can and cannot tell us

  • A different betaine formulation with multiple active components. The result cannot be attributed to ordinary anhydrous TMG alone.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Indexed abstract and bibliographic data. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial
Manal F Abdelmalek et al. · Hepatology (Baltimore, Md.) · 2009
Tier 2
Pilot trials of oral betaine in participants with metabolic dysfunction-associated steatotic liver disease and elevated alanine aminotransferase
Andrew S Lim et al. · Hepatology (Baltimore, Md.) · 2026
Tier 4
Betaine in Metabolic Dysfunction-Associated Steatotic Liver Disease: Mechanisms of Action and Therapeutic Potential
Tatjana Radosavljevic et al. · Antioxidants (Basel, Switzerland) · 2026
Tier 2
Metabolic Effects of Betaine: A Randomized Clinical Trial of Betaine Supplementation in Prediabetes
Ana Maria Grizales et al. · The Journal of clinical endocrinology and metabolism · 2018
Tier 2
Betaine supplementation decreases plasma homocysteine concentrations but does not affect body weight, body composition, or resting energy expenditure in human subjects
Ursula Schwab et al. · The American journal of clinical nutrition · 2002

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology